{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T10:24:41Z","timestamp":1742639081343},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T00:00:00Z","timestamp":1488931200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00432-017-2385-7","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T08:30:35Z","timestamp":1488961835000},"page":"1311-1318","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia"],"prefix":"10.1007","volume":"143","author":[{"given":"Verena S.","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Hasford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,8]]},"reference":[{"key":"2385_CR1","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","volume":"113","author":"M Baccarani","year":"2009","unstructured":"Baccarani M et al (2009) Comparison of imatinib 400\u00a0mg and 800\u00a0mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 113:4497\u20134504. doi: 10.1182\/blood-2008-12-191254","journal-title":"Blood"},{"key":"2385_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884. doi: 10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"2385_CR3","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1200\/JCO.2008.20.3869","volume":"27","author":"JE Cortes","year":"2009","unstructured":"Cortes JE et al (2009) High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 27:4754\u20134759. doi: 10.1200\/JCO.2008.20.3869","journal-title":"J Clin Oncol"},{"key":"2385_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE et al (2010) Phase III, randomized, open-label study of daily imatinib mesylate 400\u00a0mg versus 800\u00a0mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 28:424\u2013430. doi: 10.1200\/JCO.2009.25.3724","journal-title":"J Clin Oncol"},{"key":"2385_CR5","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE et al (2012) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 30:3486\u20133492. doi: 10.1200\/JCO.2011.38.7522","journal-title":"J Clin Oncol"},{"key":"2385_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/bjh.12618","volume":"164","author":"MW Deininger","year":"2014","unstructured":"Deininger MW et al (2014) Imatinib 800\u00a0mg daily induces deeper molecular responses than imatinib 400\u00a0mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223\u2013232. doi: 10.1111\/bjh.12618","journal-title":"Br J Haematol"},{"key":"2385_CR7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:7","journal-title":"J Epidemiol Community Health"},{"issue":"14","key":"2385_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031\u20131037. doi: 10.1056\/NEJM200104053441401","journal-title":"N Engl J Med"},{"key":"2385_CR9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/bmj.315.7099.6","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in metaanalysis detected by a simple, graphical test. Br Med J 315:6","journal-title":"Br Med J"},{"key":"2385_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/ajh.22076","volume":"86","author":"A Gafter-Gvili","year":"2011","unstructured":"Gafter-Gvili A et al (2011) High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients\u2014systematic review and meta-analysis. Am J Hematol 86:657\u2013662. doi: 10.1002\/ajh.22076","journal-title":"Am J Hematol"},{"key":"2385_CR11","unstructured":"Guidance for Industry\u2014Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2007) Center for Drug Evaluation and Research\u2014Food and Drug Administration Rockville, MD, USA"},{"key":"2385_CR12","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R et al (2011) Tolerability-adapted imatinib 800\u00a0mg\/d versus 400\u00a0mg\/d versus 400\u00a0mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29:1634\u20131642. doi: 10.1200\/JCO.2010.32.0598","journal-title":"J Clin Oncol"},{"key":"2385_CR13","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558. doi: 10.1002\/sim.1186","journal-title":"Stat Med"},{"key":"2385_CR14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"J Higgins","year":"2003","unstructured":"Higgins J, Thompson S, Deeks J, Altman DG (2003) Measuring inconsistency in meta-analyses. Br Med J 327:4","journal-title":"Br Med J"},{"key":"2385_CR15","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"TP Hughes","year":"2008","unstructured":"Hughes TP et al (2008) Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600\u00a0mg\/day of imatinib as initial therapy. Blood 112:3965\u20133973. doi: 10.1182\/blood-2008-06-161737","journal-title":"Blood"},{"key":"2385_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17:1\u201312. doi: 10.1016\/0197-2456(95)00134-4","journal-title":"Control Clin Trials"},{"key":"2385_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13936","author":"P Jain","year":"2016","unstructured":"Jain P et al (2016) Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol. doi: 10.1111\/bjh.13936","journal-title":"Br J Haematol"},{"key":"2385_CR18","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270. doi: 10.1056\/NEJMoa1002315","journal-title":"N Engl J Med"},{"key":"2385_CR19","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1200\/JCO.2010.33.4169","volume":"29","author":"H Kantarjian","year":"2011","unstructured":"Kantarjian H et al (2011) Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol 29:3173\u20133178. doi: 10.1200\/JCO.2010.33.4169","journal-title":"J Clin Oncol"},{"key":"2385_CR20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood.V126.23.476.476","volume":"126","author":"J-Y Kwak","year":"2015","unstructured":"Kwak J-Y et al (2015) Efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia patients: 12 months result of phase 3 clinical trial. Blood 126:476\u2013476","journal-title":"Blood"},{"key":"2385_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1\u2013e34. doi: 10.1016\/j.jclinepi.2009.06.006","journal-title":"J Clin Epidemiol"},{"key":"2385_CR22","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.3109\/10428194.2014.885515","volume":"55","author":"H Malhotra","year":"2014","unstructured":"Malhotra H, Sharma P, Bhargava S, Rathore OS, Malhotra B, Kumar M (2014) Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia. Leuk Lymphoma 55:2614\u20132619. doi: 10.3109\/10428194.2014.885515","journal-title":"Leuk Lymphoma"},{"key":"2385_CR23","first-page":"128","volume":"14","author":"J McDougall","year":"2016","unstructured":"McDougall J, Ramsey SD, Radich J (2016) What happens when imatinib goes generic? JNCCN 14:128\u2013131","journal-title":"JNCCN"},{"key":"2385_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2162-3619-2-5","volume":"2","author":"S Mealing","year":"2013","unstructured":"Mealing S, Barcena L, Hawkins N, Clark J, Eaton V, Hirji I, Davis C (2013) The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis. Exp Hematol Int Soc Cell 2:5\u20135. doi: 10.1186\/2162-3619-2-5","journal-title":"Exp Hematol Int Soc Cell"},{"key":"2385_CR25","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131004. doi: 10.1056\/NEJMoa022457","journal-title":"N Engl J Med"},{"key":"2385_CR26","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109:3496\u20133499. doi: 10.1182\/blood-2006-07-036012","journal-title":"Blood"},{"key":"2385_CR27","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C et al (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363:2511\u20132521. doi: 10.1056\/NEJMoa1004095","journal-title":"N Engl J Med"},{"key":"2385_CR28","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP et al (2012) A randomized trial of dasatinib 100\u00a0mg versus imatinib 400\u00a0mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 120:3898\u20133905. doi: 10.1182\/blood-2012-02-410688","journal-title":"Blood"},{"key":"2385_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1096\/fj.04-3140lfe","volume":"19","author":"ES Rosmarakis","year":"2005","unstructured":"Rosmarakis ES, Soteriades ES, Vergidis PI, Kasiakou SK, Falagas ME (2005) From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J 19:673\u2013680. doi: 10.1096\/fj.04-3140lfe","journal-title":"FASEB J"},{"key":"2385_CR30","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G et al (2010) Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259. doi: 10.1056\/NEJMoa0912614","journal-title":"N Engl J Med"},{"key":"2385_CR31","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","volume":"125","author":"J Wang","year":"2015","unstructured":"Wang J et al (2015) Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood 125:2771\u20132778. doi: 10.1182\/blood-2014-09-601674","journal-title":"Blood"},{"key":"2385_CR32","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/leu.2015.170","volume":"29","author":"DB Watkins","year":"2015","unstructured":"Watkins DB, Hughes TP, White DL (2015) OCT1 and imatinib transport in CML: is it clinically relevant? Leukemia 29:1960\u20131969. doi: 10.1038\/leu.2015.170","journal-title":"Leukemia"},{"key":"2385_CR33","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","volume":"125","author":"DT Yeung","year":"2015","unstructured":"Yeung DT et al (2015) TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 125:915\u2013923. doi: 10.1182\/blood-2014-07-590315","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2385-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2385-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2385-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T14:43:31Z","timestamp":1601736211000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2385-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,8]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["2385"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2385-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,8]]}}}